NANOBIOTIX: New Data Featuring NBTXR3 Plus Chemoradiation and in the Preoperative Setting Support Broad Applicability for Head and Neck Cancer and Other Solid Tumor Indications
Data reported at the 2022 Annual Meeting of the American Society for Clinical Oncology NBTXR3 is being developed as a product candidate with potential to integrate across the standards of care
United States Brandon Owens Kate Mcneil Porter Novelli Pierre Louis Germain French Financial Markets Authority Autorit
Source: finanznachrichten.de